ZIG
IMDX

Zuckerman Investment Group’s Insight Molecular Diagnostics IMDX Stock Holding History

Zuckerman Investment Group’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-507
Closed -$53K – 117
2021
Q1 		$53K Buy
+507
New +$48.1K 0.01% 108

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Zuckerman Investment Group's IMDX Position: Q2 2021 in Review

Zuckerman Investment Group sold out of Insight Molecular Diagnostics (IMDX) in Q2 2021, closing a stake of 507 shares — an estimated $53K sold.

Zuckerman Investment Group first reported a position in IMDX in Q1 2021 and held it in 1 quarter. The position peaked at $53K in Q1 2021. 90 funds tracked by Wall St. Rank hold IMDX as of Q2 2021.

  • Zuckerman Investment Group reported no remaining Insight Molecular Diagnostics position as of Q2 2021 after selling out during the quarter.
  • Zuckerman Investment Group sold 507 Insight Molecular Diagnostics shares in Q2 2021, an estimated $53K.
  • Zuckerman Investment Group first reported a position in Insight Molecular Diagnostics in Q1 2021 and held it in 1 quarter.
  • Zuckerman Investment Group's Insight Molecular Diagnostics position peaked at $53K in Q1 2021.
  • 90 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2021.

Based on Zuckerman Investment Group's 13F filing for Q2 2021, filed 16 Aug 2021.